← Leaderboards
Sreerama Shetty
University Of Texas Hlth Ctr At Tyler
$8,298,919
Attributed
$8,298,919
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $852.8K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,298,919 · 9
By mechanism
R01$5,164,751 · 4
P01$1,729,894 · 1
R21$1,404,274 · 4
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Hlth Ctr At Tyler
Same institution · by research overlap
- Torry Alle Tucker$3,028,800
- Steven Idell$6,820,677
- Andrey Komissarov$3,479,251
Others in their field
Top investigators on “Lung Injury”
- Polly Chang · Sri International$53,674,299
- Asrar B. Malik · University Of Illinois At Chicago$44,050,753
- Edward E Morrisey · University Of Pennsylvania$36,050,545
- Boyd Taylor Thompson · Massachusetts General Hospital$33,582,267
- David Alan Schoenfeld · Massachusetts General Hospital$28,987,839
- Jahar Bhattacharya · St. Luke'S-Roosevelt Inst For Hlth Scis$28,655,382
Research focus
Lung InjuryPathogenesisEpithelial CellsPathway InteractionsMediatingFibrinolysisLungCellsDepositionApoptosisSignal TransductionPeptidesMolecularStructure Of Parenchyma Of LungRepairedTp53 GeneAlveolarTertiary Protein StructureCaveolin 1FibroblastsAffectProteinsResponseScaffold
Grant awards (27)
CSP7 inhibits toxicity of ionizing radiation to the lung$219,024
R21 · FY2025 · CA · contact PI
Development, Formulation and Inhalational Delivery of a New Peptide for ILD$439,300
R01 · FY2024 · HL · contact PI
Development, Formulation and Inhalational Delivery of a New Peptide for ILD$448,410
R01 · FY2023 · HL · contact PI
Development, Formulation and Inhalational Delivery of a New Peptide for ILD$448,554
R01 · FY2022 · HL · contact PI
Regulation of Silica-induced Lung Injury by Plasminogen Activator Inhibitor-1$404,250
R21 · FY2022 · ES · contact PI
Development, Formulation and Inhalational Delivery of a New Peptide for ILD$460,448
R01 · FY2021 · HL · contact PI
Control of fibrosing lung disease by p53-miR-34a-targeted therapeutics$391,794
R01 · FY2019 · HL · contact PI
Control of fibrosing lung disease by p53-miR-34a-targeted therapeutics$391,794
R01 · FY2018 · HL · contact PI
Control of fibrosing lung disease by p53-miR-34a-targeted therapeutics$391,794
R01 · FY2017 · HL · contact PI
Role of p53 and PAI-1 in tobacco smoke exposure induced lung injury$178,750
R21 · FY2017 · ES · contact PI
Control of fibrosing lung disease by p53-miR-34a-targeted therapeutics$391,794
R01 · FY2016 · HL · contact PI
Role of p53 and PAI-1 in tobacco smoke exposure induced lung injury$214,500
R21 · FY2016 · ES · contact PI
Regulation of lung epithelial injury by plasminogen activator inhibitor-1$211,500
R21 · FY2011 · HL · contact PI
Regulation of lung epithelial injury by plasminogen activator inhibitor-1$176,250
R21 · FY2010 · HL · contact PI
Control of Fibrinolysis by the Lung Epithelium$351,216
P01 · FY2009 · HL · contact PI
Control of Fibrinolysis by the Lung Epithelium$339,393
P01 · FY2008 · HL · contact PI
Control of Fibrinolysis by the Lung Epithelium$374,814
P01 · FY2007 · HL · contact PI
Control of Fibrinolysis by the Lung Epithelium$337,074
P01 · FY2006 · HL · contact PI
Control of Fibrinolysis by the Lung Epithelium$327,397
P01 · FY2005 · HL
Regulation of Lung Epithelial Fibrinolysis by Urokinase$265,461
R01 · FY2005 · HL
Control of Fibrinolytic Pathways in Lung Disease$275,000
R01 · FY2004 · HL
Regulation of Lung Epithelial Fibrinolysis by Urokinase$263,414
R01 · FY2004 · HL
Regulation of Lung Epithelial Fibrinolysis by Urokinase$261,446
R01 · FY2003 · HL
Regulation of Lung Epithelial Fibrinolysis by Urokinase$259,554
R01 · FY2002 · HL
CONTROL OF FIBRINOLYTIC PATHWAYS IN LUNG DISEASE$162,367
R01 · FY2002 · HL
CONTROL OF FIBRINOLYTIC PATHWAYS IN LUNG DISEASE$158,626
R01 · FY2001 · HL
CONTROL OF FIBRINOLYTIC PATHWAYS IN LUNG DISEASE$154,995
R01 · FY2000 · HL